drugset / Trial / NCT00647699

Corneal Collagen Cross-linking for Progressive Keratoconus

NCT00647699

Phase 3 Completed 147 enrolled Glaukos Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

Prospective, randomized multicenter study to determine the safety and effectiveness of performing cornea collagen cross-linking (CXL) using riboflavin and UVA light in eyes with progressive keratoconus.

Timeline

Start
2007-12
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Riboflavin Other / unclassified 0.1 % Other
Comparator Riboflavin Other / unclassified 1.6 ml Other

Indications